HealthyPhase 4NCT06800378
Zolpidem's Effects on Road Cycling Performance
A Phase 4 study testing Zolpidem 10 mg in people with Healthy, run by National Taiwan Normal University at 1 site in Taiwan.
Trial summary
This study will recruit 15 healthy participants who regularly engage in cycling as their primary physical activity. Recruitment will take place at the hospital, where participants will sign an informed consent form and complete a health survey. Read more about this study
- Who is it for?
- Ages 20 years and older, men only
- Conditions the study is for
- Healthy
- What is being tested?
- Zolpidem 10 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 1 siteTaiwan
- Study dates
- 26 Jun 2024to 29 Dec 2024
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults over 20 years old
- Bicycle age over 2 years
- Rides more than twice a week
- Does not regularly use sedative-hypnotic drugs or first-generation antihistamines that aid in sleep
- Does not have drinking or smoking habits (≤1 time per week)
- Has competition experience (has participated in cycling competitions over 100 kilometers or other cycling races)
- Has used an indoor bicycle trainer
- Average sleep time is between 11:00 PM and 1:00 AM
Who cannot join
- Irregular sleep and shift workers
- Individuals with medical, psychiatric, and sleep disorders
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of the Sedative-Hypnotic Medication Zolpidem on Performance in Road Cycling
This study will recruit 15 healthy participants who regularly engage in cycling as their primary physical activity. Recruitment will take place at the hospital, where participants will sign an informed consent form and complete a health survey. The experiments will be conducted at the Exercise Physiology Laboratory in Gongguan, National Taiwan Normal University. Participants will need to familiarize themselves with the procedures before the formal tests. Prior to the measurements, participants must complete: (1) a Sleep Quality Questionnaire and (2) a Sleep Pattern Questionnaire.
This study follows a double-blind design and involves two formal experiments. Two weeks before the experiments, participants will complete forms regarding sleep quality, recent Functional Threshold Power (FTP) over the past 1-2 months, and will receive an explanation of the study. One week before the experiments, participants will visit Dr. Kuo-Yi Weng at the Rheumatology and Immunology Clinic of Zhongli Ten-Chan Hospital to obtain the study medication, Zolpidem .
On the evening before the first experiment, participants will report to the laboratory before 7:00 PM. At 8:59 PM, they will be randomly assigned to take either 10 mg of Zolpidem or a placebo. At 9:00 PM, participants will go to bed wearing a sleep monitoring device (Fitbit Charge 4). At 4:00 AM, they will wake up, complete the Leeds Sleep Evaluation Questionnaire (Self-reported), and have breakfast. The formal experiment will begin at 5:00 AM, during which participants will use the Zwift online platform to simulate a 60-kilometer ride to measure athletic performance. The two formal experiments will be spaced one week apart.
Read the detailed description
- Specimen Collection:
- On the test day, arm tissue glucose levels will be collected using continuous glucose monitoring (CGM), which will continue until the experiment concludes.
- Fingerstick blood samples will be taken using a lancet to measure glucose and lactate levels at 0,10,20,40,50 and 60 kilometers.
- Prohibitions, Restrictions, and Requirements for Participants During the Trial:
- Training and Sleep Patterns: Participants are required to maintain their usual training routines and sleep patterns without changing their schedules increasing training intensity. This is to control for changes in physical performance and sleep quality during the trial period.
- Diet: Participants should consume the same or similar foods the day before and the day of the trial to minimize the impact of dietary changes on the experiment. 3.Restrictions: Participants are prohibited from consuming caffeinated beverages such as tea, coffee, or energy drinks on the night before and the morning of the trial to avoid potential interference with the results.
- Conditions
- Healthy
- Being tested
- Zolpidem 10 mg, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Zolpidem 10 mgDrug
Zolpidem tartrate 10 mg tablet (taken before bedtime)
PlaceboOther
Starch 10 mg tablet (taken before bedtime)
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Other | 10 mg starch Receives: Other: Placebo |
| Drug | Experimental | 10 mg Zolpidem Receives: Drug: Zolpidem 10 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Physiological Indicator (Lactate) for 40km at 70%FTP
Lactate in mmol/L .Testing will be conducted using an indoor trainer (TACX NEO) to assess whether taking medication affects lactate changes.Lactate will be collected at 10, 20, 30, 40 kilometers, respectively. A total of four times.
Measured: Approximately 1 to 1.5 hours during each study intervention.
Physiological Indicator (Blood Glucose) for 40km at 70%FTP
Glucose in mg/dL . Testing will be conducted using an indoor trainer (TACX NEO) to evaluate whether taking medication affects blood glucose changes.The evaluation will be conducted when the participants complete 10, 20, 30, and 40 km of cycling(Using CGM). A total of four times.
Measured: Approximately 1 to 1.5 hours during each study intervention.
Rate of Perceived Exertion for 40 km at 70% FTP
Borg Scale (6-20) .Testing will be conducted using an indoor trainer (TACX NEO) to determine whether taking medication influences changes in the Rate of Perceived Exertion (RPE).The evaluation will be conducted when the participants complete 10, 20, 30, and 40 km of cycling. A total of four times.
Measured: Approximately 1 to 1.5 hours during each study intervention.
20KM Time Trial
Time trial (minute) .Testing will be conducted using an indoor trainer (TACX NEO) to assess whether taking medication affects the time trial (TT) performance.Participants performed a 20 km time trial (TT) after completing 40 km at 70% FTP, and the completion time was recorded.A total of one times.
Measured: Approximately 30 to 60 min during each study intervention.
Average Power for 20KM Time Trial
Average Power(W).Testing will be conducted using an indoor trainer (TACX NEO) to evaluate whether taking medication affects the average power output.Participants performed a 20 km time trial (TT) after completing 40 km at 70% FTP, and the average power was recorded.A total of one times.
Measured: Approximately 30 to 60 min during each study intervention.
Physiological Indicator (Blood Glucose) for 20KM Time Trial
Glucose in mg/dl . Testing will be conducted using an indoor trainer (TACX NEO) to assess whether taking medication affects blood glucose changes during the time trial.The evaluation will be conducted when the participants complete 10, 20 km of Time Trial. A total of two times.
Measured: Approximately 30 to 60 min during each study intervention.
Physiological Indicator (Lactate) for 20KM Time Trial
Testing will be conducted using an indoor trainer (TACX NEO) to evaluate whether taking medication affects lactate changes during the time trial.The evaluation will be conducted when the participants complete 10, 20 km of Time trial . A total of two times .
Measured: Approximately 30 to 60 minutes during each study intervention.
Rate of Perceived Exertion for 20km Time trial
RPE：Borg Scale (Score：6-20 ).Testing will be conducted using an indoor trainer (TACX NEO) to determine whether taking medication influences changes in the Rate of Perceived Exertion (RPE) during the time trial.The evaluation will be conducted when the participants complete 10, 20 km of Time trial . A total of two times .
Measured: Approximately 30 to 60 minutes during each study intervention.
Sleep Duration (Minutes)
Sleep Duration in Minutes.Sleep duration will be measured using Fitbit Charge 4 to evaluate the differences in sleep length between taking and not taking medication.Measurements will begin after taking medication at 9:00 PM and conclude upon waking up the next day at 4:00 AM. Sleep duration will be recorded using Fitbit Charge 4.
Measured: The monitoring duration is 7 hours during each study intervention.
Sleep Latency (Minutes):
Sleep latency in minutes . Sleep latency will be measured using Fitbit Charge 4 to evaluate the differences in the time taken to fall asleep between taking and not taking medication.Measurements will begin after taking medication at 9:00 PM and conclude upon waking up the next day at 4:00 AM. Sleep potency will be recorded using Fitbit Charge 4.
Measured: The monitoring duration is 7 hours during each study intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2025
- Study start26 Jun 2024
- Primary completion22 Dec 2024
- Study completion29 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan Normal University
- Sponsor type
- University, hospital or other
- Collaborators
- Ten-Chen General Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06800378
- Sponsor's protocol ID
- 113-A-01-02
- Status last verified
- Jan 2025
- First submitted
- 23 Dec 2024
- Last updated
- 30 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Wilms B, Chamorro R, Hallschmid M, Trost D, Forck N, Schultes B, Molle M, Sayk F, Lehnert H, Schmid SM. Timing Modulates the Effect of Sleep Loss on Glucose Homeostasis. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2801-2808. doi: 10.1210/jc.2018-02636.
PubMed 30807636Temesi J, Arnal PJ, Davranche K, Bonnefoy R, Levy P, Verges S, Millet GY. Does central fatigue explain reduced cycling after complete sleep deprivation? Med Sci Sports Exerc. 2013 Dec;45(12):2243-53. doi: 10.1249/MSS.0b013e31829ce379.
PubMed 23760468Saner NJ, Lee MJ, Kuang J, Pitchford NW, Roach GD, Garnham A, Genders AJ, Stokes T, Schroder EA, Huo Z, Esser KA, Phillips SM, Bishop DJ, Bartlett JD. Exercise mitigates sleep-loss-induced changes in glucose tolerance, mitochondrial function, sarcoplasmic protein synthesis, and diurnal rhythms. Mol Metab. 2021 Jan;43:101110. doi: 10.1016/j.molmet.2020.101110. Epub 2020 Oct 31.
PubMed 33137489Rosenberg RP, Hull SG, Lankford DA, Mayleben DW, Seiden DJ, Furey SA, Jayawardena S, Roth T. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014 Oct 15;10(10):1093-100. doi: 10.5664/jcsm.4108.
PubMed 25317090Papanikolaou DD, Astara K, Vavougios GD, Daniil Z, Gourgoulianis KI, Stavrou VT. Elements of Sleep Breathing and Sleep-Deprivation Physiology in the Context of Athletic Performance. J Pers Med. 2022 Mar 2;12(3):383. doi: 10.3390/jpm12030383.
PubMed 35330382Mougin F, Simon-Rigaud ML, Davenne D, Renaud A, Garnier A, Kantelip JP, Magnin P. Effects of sleep disturbances on subsequent physical performance. Eur J Appl Physiol Occup Physiol. 1991;63(2):77-82. doi: 10.1007/BF00235173.
PubMed 1748108Leong RLF, Cheng GH, Chee MWL, Lo JC. The effects of sleep on prospective memory: A systematic review and meta-analysis. Sleep Med Rev. 2019 Oct;47:18-27. doi: 10.1016/j.smrv.2019.05.006. Epub 2019 May 31.
PubMed 31216498Horoszok L, Baleeiro T, D'Aniello F, Gropper S, Santos B, Guglietta A, Roth T. A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. Hum Psychopharmacol. 2014 May;29(3):266-73. doi: 10.1002/hup.2395.
PubMed 24911577Holgado D, Manresa-Rocamora A, Zamboni L, Lugoboni F, Peiro AM, Zandonai T. The effect of benzodiazepines on exercise in healthy adult participants: A systematic review. J Addict Dis. 2022 Jul-Sep;40(3):336-344. doi: 10.1080/10550887.2021.1990640. Epub 2021 Nov 9.
PubMed 34751107Haraldsdottir K, Sanfilippo J, McKay L, Watson AM. Decreased Sleep and Subjective Well-Being as Independent Predictors of Injury in Female Collegiate Volleyball Players. Orthop J Sports Med. 2021 Sep 9;9(9):23259671211029285. doi: 10.1177/23259671211029285. eCollection 2021 Sep.
PubMed 34527756Grobler LA, Schwellnus MP, Trichard C, Calder S, Noakes TD, Derman WE. Comparative effects of zopiclone and loprazolam on psychomotor and physical performance in active individuals. Clin J Sport Med. 2000 Apr;10(2):123-8. doi: 10.1097/00042752-200004000-00007.
PubMed 10798794Gramaglia E, Ramella Gigliardi V, Olivetti I, Tomelini M, Belcastro S, Calvi E, Dotta A, Ghigo E, Benso A, Broglio F. Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects. J Endocrinol Invest. 2014 Feb;37(2):203-6. doi: 10.1007/s40618-013-0016-y. Epub 2014 Jan 9.
PubMed 24497220Craven J, McCartney D, Desbrow B, Sabapathy S, Bellinger P, Roberts L, Irwin C. Effects of Acute Sleep Loss on Physical Performance: A Systematic and Meta-Analytical Review. Sports Med. 2022 Nov;52(11):2669-2690. doi: 10.1007/s40279-022-01706-y. Epub 2022 Jun 16.
PubMed 35708888Collomp K, Fortier M, Cooper S, Long A, Ahmaidi S, Prefaut C, Wright F, Picot M, Cote MG. Performance and metabolic effects of benzodiazepine during submaximal exercise. J Appl Physiol (1985). 1994 Aug;77(2):828-33. doi: 10.1152/jappl.1994.77.2.828.
PubMed 8002535Chase JD, Roberson PA, Saunders MJ, Hargens TA, Womack CJ, Luden ND. One night of sleep restriction following heavy exercise impairs 3-km cycling time-trial performance in the morning. Appl Physiol Nutr Metab. 2017 Sep;42(9):909-915. doi: 10.1139/apnm-2016-0698. Epub 2017 May 3.
PubMed 28467857
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of the Sedative-Hypnotic Medication Zolpidem on Performance in Road Cycling
- ClinicalTrials.gov ID
- NCT06800378
- Acronym / sponsor ID
- 113-A-01-02
- Conditions
- Healthy
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- National Taiwan Normal UniversityUniversity, hospital or other
- Collaborators
- Ten-Chen General Hospital
- Study start
- 26 Jun 2024 (actual)
- Primary completion
- 22 Dec 2024 (actual)
- Study completion
- 29 Dec 2024 (actual)
- First posted
- 30 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will recruit 15 healthy participants who regularly engage in cycling as their primary physical activity. Recruitment will take place at the hospital, where participants will sign an informed consent form and complete a health survey. The experiments will be conducted at the Exercise Physiology Laboratory in Gongguan, National Taiwan Normal University. Participants will need to familiarize themselves with the procedures before the formal tests. Prior to the measurements, participants must complete: (1) a Sleep Quality Questionnaire and (2) a Sleep Pattern Questionnaire.
This study follows a double-blind design and involves two formal experiments. Two weeks before the experiments, participants will complete forms regarding sleep quality, recent Functional Threshold Power (FTP) over the past 1-2 months, and will receive an explanation of the study. One week before the experiments, participants will visit Dr. Kuo-Yi Weng at the Rheumatology and Immunology Clinic of Zhongli Ten-Chan Hospital to obtain the study medication, Zolpidem .
On the evening before the first experiment, participants will report to the laboratory before 7:00 PM. At 8:59 PM, they will be randomly assigned to take either 10 mg of Zolpidem or a placebo. At 9:00 PM, participants will go to bed wearing a sleep monitoring device (Fitbit Charge 4). At 4:00 AM, they will wake up, complete the Leeds Sleep Evaluation Questionnaire (Self-reported), and have breakfast. The formal experiment will begin at 5:00 AM, during which participants will use the Zwift online platform to simulate a 60-kilometer ride to measure athletic performance. The two formal experiments will be spaced one week apart.
Detailed description
- Specimen Collection:
- On the test day, arm tissue glucose levels will be collected using continuous glucose monitoring (CGM), which will continue until the experiment concludes.
- Fingerstick blood samples will be taken using a lancet to measure glucose and lactate levels at 0,10,20,40,50 and 60 kilometers.
- Prohibitions, Restrictions, and Requirements for Participants During the Trial:
- Training and Sleep Patterns: Participants are required to maintain their usual training routines and sleep patterns without changing their schedules increasing training intensity. This is to control for changes in physical performance and sleep quality during the trial period.
- Diet: Participants should consume the same or similar foods the day before and the day of the trial to minimize the impact of dietary changes on the experiment. 3.Restrictions: Participants are prohibited from consuming caffeinated beverages such as tea, coffee, or energy drinks on the night before and the morning of the trial to avoid potential interference with the results.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Other | Other: Placebo10 mg starch |
| Drug | Experimental | Drug: Zolpidem 10 mg10 mg Zolpidem |
Who may qualify
- Ages
- 20 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Adults over 20 years old
- Bicycle age over 2 years
- Rides more than twice a week
- Does not regularly use sedative-hypnotic drugs or first-generation antihistamines that aid in sleep
- Does not have drinking or smoking habits (≤1 time per week)
Key exclusion criteria (2 listed)
- Irregular sleep and shift workers
- Individuals with medical, psychiatric, and sleep disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Zolpidem 10 mgZolpidem tartrate 10 mg tablet (taken before bedtime) | Drug | Drug |
| PlaceboStarch 10 mg tablet (taken before bedtime) | Other | Placebo |
Primary outcome
Physiological Indicator (Lactate) for 40km at 70%FTP
Time frame: Approximately 1 to 1.5 hours during each study intervention.
Lactate in mmol/L .Testing will be conducted using an indoor trainer (TACX NEO) to assess whether taking medication affects lactate changes.Lactate will be collected at 10, 20, 30, 40 kilometers, respectively. A total of four times.
Physiological Indicator (Blood Glucose) for 40km at 70%FTP
Time frame: Approximately 1 to 1.5 hours during each study intervention.
Glucose in mg/dL . Testing will be conducted using an indoor trainer (TACX NEO) to evaluate whether taking medication affects blood glucose changes.The evaluation will be conducted when the participants complete 10, 20, 30, and 40 km of cycling(Using CGM). A total of four times.
Rate of Perceived Exertion for 40 km at 70% FTP
Time frame: Approximately 1 to 1.5 hours during each study intervention.
Borg Scale (6-20) .Testing will be conducted using an indoor trainer (TACX NEO) to determine whether taking medication influences changes in the Rate of Perceived Exertion (RPE).The evaluation will be conducted when the participants complete 10, 20, 30, and 40 km of cycling. A total of four times.
20KM Time Trial
Time frame: Approximately 30 to 60 min during each study intervention.
Time trial (minute) .Testing will be conducted using an indoor trainer (TACX NEO) to assess whether taking medication affects the time trial (TT) performance.Participants performed a 20 km time trial (TT) after completing 40 km at 70% FTP, and the completion time was recorded.A total of one times.
Average Power for 20KM Time Trial
Time frame: Approximately 30 to 60 min during each study intervention.
Average Power(W).Testing will be conducted using an indoor trainer (TACX NEO) to evaluate whether taking medication affects the average power output.Participants performed a 20 km time trial (TT) after completing 40 km at 70% FTP, and the average power was recorded.A total of one times.
Physiological Indicator (Blood Glucose) for 20KM Time Trial
Time frame: Approximately 30 to 60 min during each study intervention.
Glucose in mg/dl . Testing will be conducted using an indoor trainer (TACX NEO) to assess whether taking medication affects blood glucose changes during the time trial.The evaluation will be conducted when the participants complete 10, 20 km of Time Trial. A total of two times.
Physiological Indicator (Lactate) for 20KM Time Trial
Time frame: Approximately 30 to 60 minutes during each study intervention.
Testing will be conducted using an indoor trainer (TACX NEO) to evaluate whether taking medication affects lactate changes during the time trial.The evaluation will be conducted when the participants complete 10, 20 km of Time trial . A total of two times .
Rate of Perceived Exertion for 20km Time trial
Time frame: Approximately 30 to 60 minutes during each study intervention.
RPE：Borg Scale (Score：6-20 ).Testing will be conducted using an indoor trainer (TACX NEO) to determine whether taking medication influences changes in the Rate of Perceived Exertion (RPE) during the time trial.The evaluation will be conducted when the participants complete 10, 20 km of Time trial . A total of two times .
Sleep Duration (Minutes)
Time frame: The monitoring duration is 7 hours during each study intervention.
Sleep Duration in Minutes.Sleep duration will be measured using Fitbit Charge 4 to evaluate the differences in sleep length between taking and not taking medication.Measurements will begin after taking medication at 9:00 PM and conclude upon waking up the next day at 4:00 AM. Sleep duration will be recorded using Fitbit Charge 4.
Sleep Latency (Minutes):
Time frame: The monitoring duration is 7 hours during each study intervention.
Sleep latency in minutes . Sleep latency will be measured using Fitbit Charge 4 to evaluate the differences in the time taken to fall asleep between taking and not taking medication.Measurements will begin after taking medication at 9:00 PM and conclude upon waking up the next day at 4:00 AM. Sleep potency will be recorded using Fitbit Charge 4.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2025.
- Results publication: PubMed 30807636Wilms B, Chamorro R, Hallschmid M, Trost D, Forck N, Schultes B, Molle M, Sayk F, Lehnert H, Schmid SM. Timing Modulates the Effect of Sleep Loss on Glucose Homeostasis. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2801-2808. doi: 10.1210/jc.2018-02636.
- Results publication: PubMed 23760468Temesi J, Arnal PJ, Davranche K, Bonnefoy R, Levy P, Verges S, Millet GY. Does central fatigue explain reduced cycling after complete sleep deprivation? Med Sci Sports Exerc. 2013 Dec;45(12):2243-53. doi: 10.1249/MSS.0b013e31829ce379.
- Results publication: PubMed 33137489Saner NJ, Lee MJ, Kuang J, Pitchford NW, Roach GD, Garnham A, Genders AJ, Stokes T, Schroder EA, Huo Z, Esser KA, Phillips SM, Bishop DJ, Bartlett JD. Exercise mitigates sleep-loss-induced changes in glucose tolerance, mitochondrial function, sarcoplasmic protein synthesis, and diurnal rhythms. Mol Metab. 2021 Jan;43:101110. doi: 10.1016/j.molmet.2020.101110. Epub 2020 Oct 31.
- Results publication: PubMed 25317090Rosenberg RP, Hull SG, Lankford DA, Mayleben DW, Seiden DJ, Furey SA, Jayawardena S, Roth T. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014 Oct 15;10(10):1093-100. doi: 10.5664/jcsm.4108.
- Results publication: PubMed 35330382Papanikolaou DD, Astara K, Vavougios GD, Daniil Z, Gourgoulianis KI, Stavrou VT. Elements of Sleep Breathing and Sleep-Deprivation Physiology in the Context of Athletic Performance. J Pers Med. 2022 Mar 2;12(3):383. doi: 10.3390/jpm12030383.
- Results publication: PubMed 1748108Mougin F, Simon-Rigaud ML, Davenne D, Renaud A, Garnier A, Kantelip JP, Magnin P. Effects of sleep disturbances on subsequent physical performance. Eur J Appl Physiol Occup Physiol. 1991;63(2):77-82. doi: 10.1007/BF00235173.
- Results publication: PubMed 31216498Leong RLF, Cheng GH, Chee MWL, Lo JC. The effects of sleep on prospective memory: A systematic review and meta-analysis. Sleep Med Rev. 2019 Oct;47:18-27. doi: 10.1016/j.smrv.2019.05.006. Epub 2019 May 31.
- Results publication: PubMed 24911577Horoszok L, Baleeiro T, D'Aniello F, Gropper S, Santos B, Guglietta A, Roth T. A single-dose, randomized, double-blind, double dummy, placebo and positive-controlled, five-way cross-over study to assess the pharmacodynamic effects of lorediplon in a phase advance model of insomnia in healthy Caucasian adult male subjects. Hum Psychopharmacol. 2014 May;29(3):266-73. doi: 10.1002/hup.2395.
- Results publication: PubMed 34751107Holgado D, Manresa-Rocamora A, Zamboni L, Lugoboni F, Peiro AM, Zandonai T. The effect of benzodiazepines on exercise in healthy adult participants: A systematic review. J Addict Dis. 2022 Jul-Sep;40(3):336-344. doi: 10.1080/10550887.2021.1990640. Epub 2021 Nov 9.
- Results publication: PubMed 34527756Haraldsdottir K, Sanfilippo J, McKay L, Watson AM. Decreased Sleep and Subjective Well-Being as Independent Predictors of Injury in Female Collegiate Volleyball Players. Orthop J Sports Med. 2021 Sep 9;9(9):23259671211029285. doi: 10.1177/23259671211029285. eCollection 2021 Sep.
- Results publication: PubMed 10798794Grobler LA, Schwellnus MP, Trichard C, Calder S, Noakes TD, Derman WE. Comparative effects of zopiclone and loprazolam on psychomotor and physical performance in active individuals. Clin J Sport Med. 2000 Apr;10(2):123-8. doi: 10.1097/00042752-200004000-00007.
- Results publication: PubMed 24497220Gramaglia E, Ramella Gigliardi V, Olivetti I, Tomelini M, Belcastro S, Calvi E, Dotta A, Ghigo E, Benso A, Broglio F. Impact of short-term treatment with benzodiazepines and imidazopyridines on glucose metabolism in healthy subjects. J Endocrinol Invest. 2014 Feb;37(2):203-6. doi: 10.1007/s40618-013-0016-y. Epub 2014 Jan 9.
- Individual participant dataSharing planned: No
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Zolpidem 10 mg in people with Healthy, run by National Taiwan Normal University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physiological Indicator (Lactate) for 40km at 70%FTP (time frame: Approximately 1 to 1.5 hours during each study intervention.). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06800378, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.